Wells Fargo & Company Nrx Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.29 - $0.7 $3 - $9	13 Added 0.24%	5,429 $2,000
Q4 2023 Feb 09, 2024	BUY	$0.26 - $0.47 $9 - $17	37 Added 0.69%	5,416 $2,000
Q3 2023 Nov 13, 2023	BUY	$0.23 - $0.5 $8 - $19	39 Added 0.73%	5,379 $1,000
Q2 2023 Aug 15, 2023	BUY	$0.46 - $0.89 $14 - $27	31 Added 0.58%	5,340 $2,000
Q1 2023 May 12, 2023	BUY	$0.66 - $1.4 $3 - $7	5 Added 0.09%	5,309 $3,000
Q4 2022 Feb 13, 2023	BUY	$0.79 - $9.19 $9 - $110	12 Added 0.23%	5,304 $5,000
Q3 2022 Nov 14, 2022	BUY	$0.2 - $8.07 $12 - $484	60 Added 1.15%	5,292 $4,000
Q2 2022 Aug 12, 2022	BUY	$0.51 - $2.42 $118 - $561	232 Added 4.64%	5,232 $3,000
Q3 2021 Nov 15, 2021	BUY	$8.52 - $24.77 $42,600 - $123,850	5,000 New	5,000 $46,000

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $81.2M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.